Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

UNBELIEVABLE: Enanta pharmaceuticals s return on capital employed overview - Caught on Camera

Benzinga Pro data, Enanta Pharmaceuticals (NASDAQ:ENTA) reported Q2 sales of $18.72 million. Earnings fell to a loss of $33.59 million, resulting in a 11.55% decrease from last quarter. Enanta Pharmaceuticals collected $27.65 million in revenue during Q1, but reported earnings showed a $30.11 million loss.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.